AI-Enabled Nuclear Medicine Expands Precision Diagnostics

GE HealthCare has introduced a portfolio of imaging technologies, radiopharmaceuticals and artificial intelligence-enabled software designed to support the growing adoption of nuclear medicine. Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2026 in Chicago, the solutions address increasing demand for precision diagnostics, targeted therapies and theranostics across cardiology, neurology and oncology care pathways.

Scaling Nuclear Medicine for Precision Healthcare
Nuclear medicine is undergoing significant expansion as healthcare systems increase investments in molecular imaging, targeted radiopharmaceutical therapies and precision medicine. According to industry projections cited by GE HealthCare, the global nuclear medicine market is expected to grow from approximately USD 7.8 billion in 2024 to more than USD 30.7 billion by 2034.

The growth is driven by wider adoption of theranostics, which combines diagnostic imaging and targeted treatment using the same molecular pathway. As utilization increases, healthcare providers face operational challenges related to workflow standardization, radiopharmaceutical availability, infrastructure capacity and diagnostic consistency.

GE HealthCare's latest developments focus on addressing these challenges through integrated imaging systems, quantitative analytics and AI-assisted workflows that support the entire patient journey from diagnosis to treatment monitoring.

Radiopharmaceutical Access Beyond Traditional Hospital Settings
One emerging trend in nuclear medicine is the expansion of advanced imaging services into community-based healthcare environments. Improved radiopharmaceutical distribution models and mobile imaging services are making positron emission tomography (PET) more accessible outside major hospital networks.

In cardiology, GE HealthCare highlighted its PET myocardial perfusion imaging agent designed to evaluate myocardial ischemia and infarction in patients with known or suspected coronary artery disease. The technology supports routine clinical workflows through a ready-to-use unit-dose model while enabling broader access to cardiac PET imaging in community healthcare settings.

These developments reflect a broader movement toward decentralized healthcare delivery, where advanced diagnostic capabilities are increasingly available closer to patients.

Quantitative Neurology Imaging and Alzheimer's Assessment
The growing prevalence of neurodegenerative diseases is creating demand for more standardized imaging-based diagnostic tools. GE HealthCare's neurological imaging portfolio includes amyloid PET imaging agents and quantitative analysis software designed to support evaluation of Alzheimer's disease and other causes of cognitive decline.

Advanced image quantification technologies can improve consistency in amyloid plaque assessment, helping clinicians integrate molecular imaging into routine neurological care pathways. Quantitative analysis also supports longitudinal monitoring, enabling healthcare providers to assess disease progression and treatment response over time.

Theranostics and Oncology Workflow Integration
Oncology remains one of the fastest-growing application areas for nuclear medicine. Theranostics adoption is increasing as clinicians seek more personalized approaches to cancer treatment planning and response assessment.

GE HealthCare's oncology-focused portfolio combines molecular imaging systems, radiation therapy planning tools and quantitative analytics platforms designed to simplify tumor burden assessment and support standardized treatment planning. These technologies aim to improve workflow efficiency while enabling more consistent evaluation of treatment outcomes across healthcare institutions.

The company's Adaptive Theranostics framework integrates molecular imaging, quantitative analysis and multidisciplinary clinical workflows to support therapy decisions throughout multiple treatment cycles. This data-driven approach allows clinicians to monitor disease progression and adjust treatment strategies based on imaging-derived measurements.

Advanced Imaging Platforms and AI-Based Analysis
Several imaging technologies presented at SNMMI 2026 focus on improving image quality, workflow efficiency and quantitative assessment.

A new kinetic modeling software platform is designed for dynamic PET imaging and time-based radiotracer analysis. By measuring tracer behavior over time rather than relying solely on static imaging, clinicians and researchers can obtain additional quantitative information regarding biological processes.

Another newly introduced AI-powered software platform automates whole-body tumor burden analysis. The software reduces the need for manual lesion segmentation and image registration while accelerating access to quantitative measurements that support clinical decision-making.

The company's PET/CT platform, with more than 500 installations worldwide, incorporates deep-learning image processing technologies designed to improve lesion detection and image quality while reducing scan duration. According to GE HealthCare, phantom testing demonstrated PET scan time reductions of up to 53 percent and average small-lesion detectability improvements of approximately 16 percent compared with earlier systems.

Digital SPECT/CT and Localized Radiopharmaceutical Production
To support the growing demand for theranostic procedures, GE HealthCare also highlighted a digital SPECT/CT platform equipped with twelve cadmium zinc telluride (CZT) detectors. The system is designed to provide high-quality three-dimensional imaging, shorter acquisition times and quantitative capabilities that support treatment planning and monitoring.

In parallel, the company presented a compact cyclotron technology under development intended to simplify on-site production of PET tracers and radiometals, including Gallium-68. Localized production could reduce dependency on centralized manufacturing facilities while expanding access to radiopharmaceuticals in regional healthcare settings.

Building Infrastructure for Future Growth
As nuclear medicine adoption accelerates, healthcare systems increasingly require scalable infrastructure capable of supporting radiopharmaceutical manufacturing, advanced imaging analytics and standardized clinical workflows.

GE HealthCare emphasized that future growth will depend not only on individual products but also on the development of integrated ecosystems connecting tracer production, imaging systems, quantitative analysis tools and multidisciplinary clinical decision support. Such ecosystems are expected to play an increasingly important role in neurodegenerative disease management, oncology and theranostic applications.

The company's strategy centers on combining molecular imaging, artificial intelligence and connected workflows to enable broader access to precision medicine while supporting consistent clinical interpretation across institutions.

Additional Context: This section details technical specifications and competitive benchmarking not included in the original product announcement
The nuclear medicine technology market includes major competitors such as Siemens Healthineers, Philips, Canon Medical Systems, Bracco Imaging, Curium and United Imaging Healthcare. Competitive benchmarking typically focuses on PET sensitivity, lesion detectability, quantitative imaging capabilities, AI integration, radiopharmaceutical portfolios and support for theranostic workflows.

Digital PET/CT systems increasingly compete on sensitivity, scan duration and quantitative performance. Modern platforms commonly employ silicon photomultiplier detectors, deep-learning reconstruction algorithms and advanced motion correction technologies. Improvements in sensitivity can reduce scan time or radiotracer dose while maintaining diagnostic image quality.

In theranostics, differentiation increasingly depends on the ability to integrate molecular imaging, treatment planning and longitudinal patient monitoring into a unified workflow. Quantitative analytics software and AI-assisted lesion assessment are becoming key evaluation criteria because they help standardize interpretation and reduce variability between institutions.

The development of localized radiopharmaceutical production technologies, including compact cyclotrons and distributed manufacturing models, is also emerging as an important competitive factor. These systems may improve access to short-lived PET tracers and support broader adoption of precision diagnostics in regional healthcare networks.

Edited by Sucithra Mani, Induportals editor – adapted by AI.

www.gehealthcare.com